Risk factors

AI use in sales, support and supply chain brings new operational, cybersecurity, legal and reputational exposure.

Class A shares outstanding rose from 83.5 million to 87.5 million, while the disclosed resale and equity-plan share amounts were unchanged.

Teva, Apotex and MSN have launched generic HETLIOZ® versions, following adverse patent rulings.

2025 tariffs are now described as imposed, with reciprocal tariffs and temporary pauses creating continuing uncertainty.

Newly flags AI deployment, privacy, confidentiality, regulatory and investment risks; drops the public-health-crisis risk.

U.K. operations rose to approximately 20.0% of revenue from 10.9%; Canada fell to 6.8% from 7.0%.

Fixed-price, multi-year contracts now explicitly emphasize cost overruns from inflation, raw materials, technology, and subcontractors.

AI use is expanding, bringing model-quality, reputational, liability and EU regulatory risks.

New risks highlight Chilean brine limits that could cut or halt lithium pumping, portfolio exits and plant shutdowns, and AI deployment and compliance challenges.

The Utica Shale property was written down by $87 million in 2025, and the company warns asset sales could trigger further impairment charges.

A new risk warns tariffs on foreign-produced films or content could raise production costs, with mitigation through production changes potentially insufficient.

CommScope financing is expected to lift 2026 net interest expense from $367.8 million to about $800 million.